Protalix BioTherapeutics, Inc. Cash and Restricted Cash
Protalix BioTherapeutics, Inc. (PLX) had Cash and Restricted Cash of $27.42 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27.42M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.00M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.68M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.65M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $27.42M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $41.00M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $14.68M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $13.65M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $17.89M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $19.46M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $19.76M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $27.41M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $23.40M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $27.21M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $23.63M 10-K · filed 2026-03-18 |
| 2023-09-30 | $20.41M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $48.18M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $33.04M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $17.11M 10-K · filed 2026-03-18 |
| 2022-09-30 | $10.72M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $12.49M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $16.89M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $38.98M 10-K · filed 2025-03-17 |
| 2021-09-30 | $10.64M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $33.88M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $19.83M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $18.27M 10-K · filed 2024-03-14 |
| 2019-12-31 | $17.79M 10-K · filed 2023-02-27 |
| 2018-12-31 | $37.81M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |